普伐他汀对糖尿病肾病患者血清CRP和TNF-α水平的影响研究  

Effect of Pravastatin on Serum Levels of CRP and TNF-α in Patients with Diabetic Nephropathy

作　　者：韩方璇[1] 林慧[1] 汝玲[1] 

机构地区：[1]海南省人民医院,海口市570311

出　　处：《中国药房》2008年第35期2771-2773,共3页China Pharmacy

摘　　要：目的:观察普伐他汀对糖尿病肾病患者血清C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)的影响,探讨普伐他汀治疗糖尿病肾病的可能机制。方法:采用普伐他汀结合常规治疗28例为治疗组,另外单用常规治疗28例作为对照组,于治疗24周后检测患者血清中CRP、TNF-α水平。结果:治疗组与对照组的总有效率分别为67.9%、42.9%(P<0.05);与对照组比较,治疗后治疗组CRP、TNF-α显著降低(P<0.05);治疗组CRP、TNF-α的降低与24h尿蛋白量的降低及疗效呈正相关。结论:普伐他汀结合常规治疗对糖尿病肾病有效,可能与普伐他汀抑制炎性反应有关。OBJECTIVE： To investigate the effects of pravastatin on serum levels of CRP and TNF -α in patients with diabetic nephropathy and study its possible mechanism in the treatment of diabetic nephropathy. METHODS： 28 patients with diabetic nephropathy were treated with provastatin plus routine therapy （trial group）, another 28 patients with diabetic nephropathy were treated with routine therapy alone （control group） . Serum levels of CRP and TNF-α in the two groups were detected after treatment for 24 weeks. RESULTS： The total effect rate in the trial group was 67.9% versus 42.9% in the control group（P 〈 0.05）. After treatment, serum levels of CRP and TNF-α in the trial group were significantly lower than in the control group（P〈0.05）, and this decrease was positively correlated to both the decrease of 24 h urine protein and the curative efficacy. CONCLUSION： Addition of pravastatin to routine therapy is effective for patients with diabetic nephropathy, which might be correlated to its inhibition on inflammatory reaction.

关 键 词：普伐他汀 C反应蛋白 肿瘤坏死因子-Α 糖尿病肾病 

分 类 号：R972.6[医药卫生—药品] R692[医药卫生—药学]